Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

Children hospitalized with RSV showed higher risk for ICU admission, IMV, and supplemental oxygen than children hospitalized with COVID-19 or influenza.

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

An RSV vaccine has been available to pregnant women in Northern Ireland since last September and is offered from 28 weeks of ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Children younger than 5 exhibited higher risk for hospital readmission after initial admission for respiratory syncytial virus than after initial admission for influenza or human metapneumovirus, ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals. In a retrospective study published in the Journal of the American ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...